Phase I trial of targeted alpha-particle therapy using actinium-225 (Ac-225)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML) Meeting Abstract


Authors: Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Douer, D.; Estey, E. H.; Kantarjian, H. M.; Wahl, R. L.; Earle, D.; Cicic, D.; Scheinberg, D. A.
Abstract Title: Phase I trial of targeted alpha-particle therapy using actinium-225 (Ac-225)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML)
Meeting Title: 56th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 124
Issue: 21
Meeting Dates: 2014 Dec 6-9
Meeting Location: San Francisco, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2014-12-06
Language: English
ACCESSION: WOS:000349242701171
PROVIDER: wos
Notes: Meeting Abstract: 5293 -- Source: Wos
MSK Authors
  1. Jae Hong Park
    125 Park
  2. Dan Douer
    79 Douer
Related MSK Work